DOXAZOSIN AND MELOXICAM COMBINATION THERAPY FOR BPH TREATMENT WITH LUTS

• Main Authors: Wayan Suarsana, Sunaryo Hardjowijoto, Soetojo, Budiono
• Format: Article PeerReviewed
• Language: English; English; English
• Published: Ikatan Ahli Urologi Indonesia 2014
• Subjects: R Medicine (General); RD520-599.5 Surgery by region, system, or organ
• Online Access: http://repository.unair.ac.id/89483/3/Doxazosin%20and%20Meloxicam%20Combination%20Therapy%20For%20BPH%20Treatment%20With%20Luts_compressed.pdf; http://repository.unair.ac.id/89483/4/Doxazosin%20and%20Meloxicam%20Combination%20Therapy%20For%20BPH%20Treatment%20With%20Luts.pdf; http://repository.unair.ac.id/89483/7/Doxazosin%20and%20Meloxicam%20Combination%20.pdf; http://repository.unair.ac.id/89483/; http://juri.primasol.co.id/index.php?journal=juri&page=article&op=view&path%5B%5D=22; https://doi.org/10.32421/juri.v21i1.22
• Institution: Universitas Airlangga

Objective: To compare the efficacy of combination therapy of 4 mg doxazosin + 15 mg meloxicam with 4 mg doxazosin single therapy for benign prostate hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS). Materials & Methods: A prospective, randomized and double blind study with total of 22 BPH patients with LUTS were randomized to receive 4 mg doxazosin + placebo once daily for 6 weeks or a combination of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks. Inclusion criteria included IPSS ≥ 8, age > 50 years, prostate blood flow grade II. Therapeutic efficacy was assessed by comparing changes in IPSS, maximal urinary flow (Q-max) and changes in prostate blood flow between baseline and immediately after 6 weeks of therapy. Results: There was no significant difference in IPSS change between the two treatment groups (delta IPSS 4 ± 1.1 versus 3.7 ± 1.5, p = 0.630). There was a significant difference in Q-max changes between the two groups (delta Q-max 4 ± 1.5 versus 2.1 ± 0.7, p < 0.001). In group therapied with 4 mg doxazosin + 15 mg meloxicam prostate blood flow decreased from grade II to grade I in 9 of 11 patients (81%). Whereas, in the treatment group of 4 mg doxazosin + placebo no reduction was found in prostate blood flow. Conclusion: Combination therapy of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks is better than 4 mg doxazosin therapy alone in improving Q-max and decreasing prostate blood flow in BPH patients with LUTS.